Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II study of ZG005 combined with golidocitinib hydrochloride in relapsed or refractory lymphoma
CTR20250882Phase 2Active
- Sponsor
- Zelgen
- Start
- May 2025
- Modality
- Small Molecules, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of nilvanstomig, golidocitinib in lymphoma, classical Hodgkin lymphoma (cHL), primary mediastinal large B-cell lymphoma (PMBCL), extranodal natural killer/T-cell lymphoma (ENKTL), sponsored by Zelgen. Started May 2025; status: active.
02
Drugs
nilvanstomiggolidocitinib
03
Conditions
lymphomaclassical Hodgkin lymphoma (cHL)primary mediastinal large B-cell lymphoma (PMBCL)extranodal natural killer/T-cell lymphoma (ENKTL)
Beyond the preview
Go deeper on CTR20250882.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20250882.